This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Musculoskeletal disease	Bone morphogenetic protein 2 (BMP2); BMP7 (OP-1); CREB binding protein (CREBBP; CBP)	<p>Mouse studies suggest BMP2 and BMP7 could help prevent skeletal dysplasias caused by <i>CBP</i> mutations. In a mouse model of Rubinstein-Taybi syndrome induced by <i>Cbp</i> deficiency, <i>in utero</i> delivery of recombinant human BMP2 and BMP7 partially corrected embryonic skeletal dysplasias compared with delivery of saline control. Next steps include assessing the effects of BMP-based therapy on the development of other organs and on fetal viability.</p> <p>SciBX 4(48); doi:10.1038/scibx.2011.1357 Published online Dec. 15, 2011</p>	Unpatented; available for licensing	<p>Shim, J.-H. <i>et al.</i> <i>J. Clin. Invest.</i>; published online Dec. 1, 2011; doi:10.1172/JCI59466 Contact: Laurie H. Glimcher, Harvard School of Public Health, Boston, Mass. e-mail: lglimche@hsph.harvard.edu Contact: Jae-Hyuck Shim, same affiliation as above e-mail: jshim@hsph.harvard.edu</p>